Perdaman Pharmaceuticals Private Limited, a active private limited company, was established on 04 March 2008 in New Delhi, Delhi, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U24233DL2008PTC174864. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹15.00 Cr and a paid-up capital of ₹12.03 Cr.
Formerly known as Perdaman Financial Services And Holdings Private Limited. It upholds a compliant status. Its leadership includes Vikas Rambal (Director), Manoj Kumar Rambal (Director), Usha Rambal (Director). Past directors included Indeevar Kaul, Vikas Rambal, Manish Kumar Gupta. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at N-9, Ground Floor Panchsheel Park, New Delhi, Delhi, 110017.
U24233DL2008PTC174864
174864
04 March 2008
₹15.00 Cr
₹12.03 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Perdaman Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vikas Rambal | Director | 01 Dec 2015 | Current |
| Manoj Kumar Rambal | Director | 15 May 2010 | Current |
| Usha Rambal | Director | 14 Oct 2010 | Current |
| Samir Madhukar Garud | Director | 20 Jun 2013 | Current |
| Sarojni Rambal | Director | 24 Jan 2017 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 01 Jan 2017 | Past |
| Pramod Abcsdd | Director | 15 Oct 2010 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Director | 15 Oct 2010 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Perdaman Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.2% increase. The company also saw a substantial improvement in profitability, with a 18.88% increase in profit. The company's net worth moved up by a moderate rise of 3.2%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Perdaman Pharmaceuticals had a public holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Perdaman Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Perdaman Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Perdaman Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Dhruv Garg was appointed as a Company Secretary was appointed as a Company Secretary on 25 Mar 2025 & has been associated with this company since 8 months 6 days . was documented.
The activity Perdaman Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Perdaman Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was documented.
Sarojni Rambal was appointed as a Director was appointed as a Director on 24 Jan 2017 & has been associated with this company since 8 years 10 months . was recorded as a recent event.
Progress on Vikas Rambal was appointed as a Director was appointed as a Director on 01 Dec 2015 & has been associated with this company since 9 years 11 months . was documented.
Progress on Samir Madhukar Garud was appointed as a Director was appointed as a Director on 20 Jun 2013 & has been associated with this company since 12 years 5 months . was documented.
The CIN of Perdaman Pharmaceuticals Private Limited is U24233DL2008PTC174864.
Perdaman Pharmaceuticals Private Limited is headquartered at N-9, Ground Floor Panchsheel Park, New Delhi, Delhi, 110017.
Perdaman Pharmaceuticals Private Limited was incorporated on 04 March 2008.
The current directors of Perdaman Pharmaceuticals Private Limited are
The primary industry of Perdaman Pharmaceuticals Private Limited is Trade.
Perdaman Pharmaceuticals Private Limited is unlisted.
The authorized capital of Perdaman Pharmaceuticals Private Limited is ₹15.00 Cr, and the paid-up capital is ₹12.03 Cr.
The compliance status of Perdaman Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX